Abiomed's heart pump gets EU nod
(Reuters) - Abiomed Inc said European health regulators approved the use of its heart pump in cardiac surgery.
The Danvers, Massachusetts-based company said the device, called Impella cVAD, is expected to be commercially available in Europe by this summer.
The device is intended for use in cardiac surgery for supporting the weakened heart's left ventricle, which is responsible for pumping oxygen-rich blood from the lungs throughout the body.
Impella cVAD is still not approved in the United States.
Abiomed shares closed at $20.90 on Wednesday on the Nasdaq.
(Reporting by Anand Basu in Bangalore; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this
- Japan's NTT DoCoMo to exit India telecoms joint venture - sources
- Apple, Google agree to pay over $300 million to settle conspiracy lawsuit
- UPDATE 2-FCC pushes back against criticism over Internet traffic plan
- Scolari says has chosen Brazil's World Cup squad
- New Microsoft CEO Nadella impresses Wall Street, stresses challenges